Finn Søndergaard – CEO, Intsel Chimos, France
Finn Søndergaard, CEO of Intsel Chimos, shares the motivation behind the company’s two recent acquisitions of Diverchim and Centre Lab, and the new strategic opportunities to expand as a full-service…
Intsel Chimos is an independent French laboratory with a long history of expertise in the import of medicines for patients in a therapeutic impasse and a partner of choice for hospitals. In 2010 and 2011, Intsel Chimos obtained orphan drug status from the EMA and the FDA respectively for a molecule intended for the treatment of gliomas (brain tumours), which marks the beginning of their transformation into a promising biotech player in France.
Contact
162 Bureaux de la Colline • 92213 SAINT CLOUD CEDEX • France
Tel: 01 49 11 66 80
Web: intselchimos.com
Email: contact@intselchimos.com
Finn Søndergaard, CEO of Intsel Chimos, shares the motivation behind the company’s two recent acquisitions of Diverchim and Centre Lab, and the new strategic opportunities to expand as a full-service…
Mr. Finn Søndergaard, CEO of Intsel Chimos, an independent French laboratory with a long history of expertise in the import of medicines for patients in a therapeutic impasse, highlights Intsel…
Thierry Philip, president of Institut Curie, talks about the organization, the effect of cancer on Social Security and the need for a cohesive European plan involving all oncology research institutions…
Ipsen global CEO David Meek provides a fascinating look into the French pharmaceutical ecosystem, Ipsen’s bold global expansion plans, its R&D transformation, and the exciting changes to come. From…
Dr. Catherine Jessus, Director of the INSB (Institute of Biological Sciences), the largest branch of the CNRS (National Center for Scientific Research) in France, discusses the strengths and weaknesses of…
Eric Bothorel, Deputy at the French Assemblée Nationale and responsible for the parliamentary group on data, knowledge & AI, provides an exclusive interview on France’s digitalization process. Bothorel describes France’s…
Dr. Julien Borowczyk, Secretary of the Social Affairs Commission at the French Assemblée Nationale, offers his insights on the upcoming changes to the French healthcare system. He walks our audience…
Genethon, a laboratory created by the patient organization AFM-Telethon, is one of the world’s leaders in the development of biotherapies for rare diseases. In this interview Genethon’s CEO Frédéric Revah…
Philippe Lamoureux, director of LEEM, the pharmaceutical industry’s association in France, reflects on the winds of change in the sector after the establishment of the Macron government, the 2018 Strategic…
Jacques Vernin, president of FACOPHAR Santé – the French association representing companies involved in the natural and herbal health space, explains its role and the future of the organization in…
Prof. Alexis Brice, director of the French Brain & Spine Institute (Institut du Cerveau et de la Moelle épinière (ICM)), reveals the recipe behind the success of the center since…
Emmanuel Eumont, general manager of Gedeon Richter France, discusses the group’s leading position in women’s health, its external growth strategy, notably through the acquisition of Finox Biotech in 2016, and…
Dominique Martin, CEO of the ANSM (Agence Nationale de Sécurité du Médicament et des Produits de Santé) provides a fascinating insight into the French process of authorizing drugs and medical…
Dr. Denis Comet, President of AFCRO (the French Association of CROs), talks about the evolution of the clinical research environment in France and the new government actions aimed at speeding…
See our Cookie Privacy Policy Here
